I-BET 151 dihydrochloride is primarily used in research settings as a potent and selective inhibitor of the BET (bromodomain and extra-terminal) family of proteins. These proteins play a critical role in regulating gene expression, particularly in the context of inflammation and cancer. By inhibiting BET proteins, I-BET 151 dihydrochloride helps researchers study the mechanisms underlying these processes and explore potential therapeutic strategies. In cancer research, it is employed to investigate its effects on tumor growth and progression, particularly in hematologic malignancies and solid tumors. It has shown promise in reducing the expression of oncogenes and suppressing cancer cell proliferation. Additionally, it is used in studies focused on inflammatory diseases, where BET proteins are known to modulate immune responses. Researchers also utilize it to understand its role in epigenetic regulation and its potential in treating diseases driven by aberrant gene expression. Its application extends to drug discovery, where it serves as a tool for validating BET inhibition as a therapeutic approach.